Gallium

Pharmacological Applications#

Galbofloxacin#

A gallium-siderophore-fluoroquinolone conjugate: gallium is conjugated to a hydroxamate siderophore that is itself linked to a fluoroquinolone antibiotic. The result is dual targeting—Ga3+ mimics iron to gain entry, and once inside, the fluoroquinolone inhibits DNA gyrase.^{[4]Pandey et al. 2021 — Galbofloxacin: Rationally Designed Gallium-Siderophore Antibiotic Against S. aureusPandey, A., et al. · 2021Open reference 4 ↓}

Against Staphylococcus aureus, galbofloxacin achieves an MIC of 93 nM versus 920 nM for ciprofloxacin alone—a 10-fold potency improvement through siderophore-mediated targeted delivery. The specificity of the siderophore determines which bacteria import the conjugate, theoretically enabling pathogen-selective activity.

Cefiderocol#

FDA-approved in 2019. A siderophore-cephalosporin conjugate (catechol siderophore linked to a cephalosporin) that exploits bacterial iron transporters—specifically the catechol siderophore receptors of Gram-negative bacteria—to bypass porin-mediated resistance.^{[1]de Carvalho & Fernandes 2014 — Siderophores as Trojan Horses Against MDR Pathogensde Carvalho, C.C.C.R., Fernandes et al. · 2014Open reference 1 ↓}

Active against carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae—the most feared hospital-acquired pathogens in the antimicrobial resistance crisis. Phase 3 trial (CREDIBLE-CR, n=152) demonstrated clinical success rates comparable to best available therapy.

Gallium Nanoparticles#

Enhanced antimicrobial activity through sustained Ga3+ release, increased surface area, and potential membrane interaction that supplements the iron-mimic mechanism.^{[2]Ikhazuagbe et al. 2025 — Gallium Nanoparticles as Antimicrobial AgentsIkhazuagbe, I., et al. · 2025Open reference 2 ↓} Nanoparticle formulations also enable controlled local delivery—relevant for implant coatings and wound care.

Gallium-Hydroxyapatite (Ga/HA) Bioceramics#

Used in implant coatings to prevent MRSA and P. aeruginosa implant infections; disrupts bacterial iron metabolism at the implant surface through sustained Ga3+ release from the ceramic matrix.^{[5]Nguyen 2024 — Engineering Antibacterial Bioceramics: Design Principles and Mechanisms of ActionNgoc Huu Nguyen, Zufu Lu, Aaron Elbourne et al. · 2024Open reference 5 ↓} Addresses the critical clinical problem of implant-associated infection without requiring systemic antibiotic exposure.

Gallium-Polyphenol Probiotics (LGG@Ga-poly)#

A novel delivery approach: Lactobacillus rhamnosus GG engineered with a gallium-polyphenol surface network. The gallium coating selectively eradicates tumor-promoting Proteobacteria within the pancreatic tumor microenvironment while preserving the probiotic core.^{[6]Probiotics functionalized with a gallium-polyphenol network modulate the intratumor microbiota and promote anti-tumor immune responses in pancreatic cancerZi-Yi Han, Zhuang-Jiong Fu, Yu-Zhang Wang et al. · 2024Open reference 6 ↓} In preclinical pancreatic cancer models, this approach.

Reduced microbiota-derived LPS in the tumor microenvironment. Decreased PD-L1 and IL-1β expression. Improved CD8+ cytotoxic T cell infiltration.

Enhanced efficacy of anti-PD-1 immune checkpoint blockade.

This represents a convergence of gallium antimicrobial chemistry with the emerging field of intratumoral microbiome modulation.

Microbiome Selectivity: The Key Advantage#

The most compelling property of siderophore-gallium strategies is their taxonomic selectivity. Different bacterial genera use different siderophore structures and receptor systems:

• Enteric pathogens (Enterobacteriaceae) use enterobactin-type catechol siderophores
• Pseudomonas uses pyoverdine and pyochelin
• Staphylococcus uses staphyloferrin-type siderophores
• Commensals like Lactobacillus and Bifidobacterium have minimal or absent siderophore-dependent iron acquisition

Salmochelin conjugates—derived from the enterobactin of E. coli—selectively kill Enterobacteriaceae while sparing Lactobacillus and other commensals.^{[7]Passari et al. 2023 — Siderophores: Medical Applications Beyond AntimicrobialsPassari, A.K., et al. · 2023Open reference 7 ↓} This intrinsic selectivity is not achievable with conventional antibiotics, which kill broadly regardless of pathogen status.

Connection to WikiBiome Metallomics Framework#

Gallium therapeutics represent a deliberate application of mis-metallation as antimicrobial strategy—the same principle that makes cadmium and lead toxic to humans (displacement of correct metal cofactors) is weaponized here against bacterial pathogens.

The difference is directionality: toxic metal contamination poisons human enzymes through mis-metallation; gallium therapy poisons bacterial enzymes through the same mechanism, but selectively in organisms with iron-dependent biochemistry.

This positions gallium as a therapeutic inversion of the nutritional immunity concept: where the host withholds iron from pathogens, gallium provides a counterfeit iron that poisons rather than feeds.

Cross-References#

• Iron—The metal gallium mimics; ionic radius and coordination chemistry similarity enable the deception
• Siderophores and Metallophores—The uptake systems gallium exploits for pathogen-selective delivery
• Mis-Metallation—The mechanism by which gallium poisons bacterial iron-dependent enzymes
• Nutritional Immunity (Metal Sequestration)—The host strategy gallium therapeutically amplifies
• Pseudomonas aeruginosa—Primary target; biofilm-active; Phase 1/2 CF trial conducted
• Acinetobacter—Carbapenem-resistant target; cefiderocol active
• Staphylococcus aureus—Target of galbofloxacin (93 nM MIC)
• Klebsiella pneumoniae—Cefiderocol target
• Bismuth—Synergistic partner in siderophore-antibiotic combinations
• Antimicrobial Resistance—The crisis driving siderophore-gallium development
• Biofilm—Gallium disrupts iron-dependent biofilm maintenance
• Pancreatic Cancer—LGG@Ga-poly modulates intratumoral Proteobacteria